Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284
– Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm – http://www.debiopharm.com), part of Debiopharm Group™, a…